摘要
血尿酸水平升高会引起高尿酸血症，尿酸氧化酶能将尿酸分解进而降低血尿酸水平。近年来，随着生物技术的发展，尿酸氧化酶作为分解尿酸的生物制剂已被批准上市，但其有效性和安全性还有待进一步研究和评估。此文对近年用于治疗高尿酸血症的上市尿酸酶类药品及其临床应用疗效和安全性进行综述，并对尿酸氧化酶应用存在的问题和今后的研究方向做了展望。
Hyperuricemia is a condition of abnormally high uric acid level in blood. Urate oxidase catalyzes enzymatic oxidation of uric acid to provide sustained reduction of plasma uric acid level. With the development of biotechnology, urate oxidase has been approved as a urate-lowering biological agent. Its efficacy and safety need further research and evaluation. This review summarizes the clinical applica- tion and efficacy and safety of urate oxidase as urate-lowering agent for hyperuricemia in recent years. The problems of application and future research directions are also discussed.
出处
《国际生物制品学杂志》
CAS
2016年第2期92-96,共5页
International Journal of Biologicals
基金
上海市科技支撑计划（15431906200）
